Business
Organon Enters into a Commercialization Agreement for Daiichi Sankyo’s Nilemdo® in France, Denmark, Iceland, Sweden, Finland and Norway
JERSEY CITY, N.J., January 08, 2026--Organon enters into agreement to expand access to a new, first-in-class treatment in certain European countries; builds on cardiovascular portfolio
About this update from Organon & Co.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/f82cdfb02202718254f1fd4b27621b6d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/B_LdQZ7w6zoUQulPfk7mDw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/f82cdfb02202718254f1fd4b27621b6d","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/xCVz3tDdKA6yn7qrYmuaJQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/f82cdfb02202718254f1fd4b27621b6d","width":1024,"height":512}},"lazy":false},{"type":"text","content":"The agreement builds on Organon’s cardiovascular disease portfolio, leveraging expertise to expand access to new treatments for patients with dyslipidemia, especially statin-intolerant patients.","length":194,"tagName":"p","attribs":{}},{"type":"text","content":"This collaboration addresses a critical gap in care that disproportionately affects women, who are at a 47% higher risk of developing statin intolerance compared to men.i","length":170,"tagName":"p","attribs":{}},{"type":"text","content":"JERSEY CITY, N.J., January 08, 2026--(BUSINESS WIRE)--Organon today announced that it has entered into an agreement with Daiichi Sankyo Europe to commercialize Nilemdo® (bempedoic acid) in France, Denmark, Iceland, Sweden, Finland and Norway. Nilemdo® is a new, first-in-class drug indicated for patients with high cholesterol and cardiovascular disease risk. It provides an alternative treatment for patients that cannot be treated effectively with statins.ii","length":460,"tagName":"p"},{"type":"text","content":""This collaboration combines Organon’s commercial agility with Daiichi Sankyo’s expertise in cardiovascular innovation to bring Nilemdo® to patients in France, Denmark, Iceland, Sweden, Finland and Norway," says Thibault Crosnier Leconte, AVP & Managing Director at Organon Northwest Europe. "By offering a new treatment option for patients who cannot tolerate statins, we are helping to close a persistent gap in cardiovascular care—one that disproportionately affects women – whilst reinforcing our mission to deliver impactful treatments for a healthier every day."","length":592,"...